Drugs / Topefilgrastim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07384936 | Jan 2026 → May 2027 expected | preeclampsia | Fang Wang | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Topefilgrastim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07384936 ↗ |
| Route | Subcutaneous | “Subjects will receive subcutaneous injection of 0.5 mg Topefilgrastim starting from Week 1 Day 1 (W1D1), with a frequency of once every two weeks, for at least 8 consecutive weeks.” NCT07384936 ↗ |